SecBot SecBot
PRESS-RELEASE ·Filed Jul 29, 2026

DYN

Dyne Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The BLA acceptance with Priority Review for z-rostudirsen is the primary catalyst, setting up a binary PDUFA event in January 2027. The $431M offering provides ample cash through 2028 but dilutes existing holders by ~13%. Watch for topline ACHIEVE data in Q1 2027 for DM1, which could further de-risk the pipeline. The stock may trade on regulatory milestones rather than quarterly financials.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

DYN drug pipeline →

z-rostudirsen

▲ Bullish Named in this press release
Impact
Phase
Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
Time to market
Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
Next catalyst
PDUFA date · Jan 21, 2027 66d

What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.73
T+0 close · Jul 29, 2026 · via day close
Latest settled
−39.29%
T+60 · $15.62
Vs SPY
−41.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $25.73entry
  2. T+1 · 4mo ago −2.14%α −2.84% · $25.18
  3. T+5 · 3mo ago +0.58%α −3.04% · $25.88
  4. T+20 · 3mo ago +1.40%α −2.57% · $26.09
  5. T+60 · 25d ago −39.29%α −41.76% · $15.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics reported Q2 2026 net loss of $1.08 per share, slightly narrower than the $0.97 loss in Q2 2025 but above the consensus estimate of -$0.75. The key catalyst is the FDA acceptance of the BLA for z-rostudirsen in DMD with Priority Review and a PDUFA date of January 21, 2027, alongside completion of enrollment in the ACHIEVE trial for DM1. The company also completed a $431M public offering and expanded its debt facility to $400M, extending cash runway into Q2 2028.

Key Financial Metrics

EPS
−$1.08
est −$0.75 · -44.0%
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • BLA for z-rostudirsen (exon 51 DMD) accepted with Priority Review; PDUFA date January 21, 2027
  • Completed enrollment of 71 participants in ACHIEVE registrational expansion cohort for DM1; topline data Q1 2027
  • IND cleared for DYNE-302 in FSHD; Phase 1 trial planned
  • Completed $431M public offering (21M shares at $20.50) in July 2026
  • Expanded Hercules debt facility to $400M
  • Cash position $898.5M at June 30, 2026; cash runway into Q2 2028
  • Net loss $178.6M ($1.08/share) vs $110.9M ($0.97/share) in Q2 2025

Financial Impact

EPS beat consensus by $0.02 (2.6%), but net loss widened 61% YoY to $178.6M due to increased R&D and G&A spend ahead of potential commercial launch

net lossR&D expensescash positiondilution

Risk Factors

  • PDUFA delay or Complete Response Letter for z-rostudirsen
  • Dilution from $431M offering (21M new shares)
  • ACHIEVE topline data miss in Q1 2027
  • R&D spend continues to rise without near-term revenue
  • Competition from other DMD exon-skipping therapies

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3335623

Track record

54 reports on DYN

Performance horizon

11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (10h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026